Target Name: LCE3D
NCBI ID: G84648
Review Report on LCE3D Target / Biomarker Content of Review Report on LCE3D Target / Biomarker
LCE3D
Other Name(s): Late envelope protein 16 | LEP16 | small proline rich-like (epidermal differentiation complex) 6B | OTTHUMP00000014324 | Late cornified envelope 3D | small proline-rich-like epidermal differentiation complex protein 6A | Small proline-rich-like epidermal differentiation complex protein 6A | LCE3D_HUMAN | MGC126833 | SPRL6A | small proline-rich-like epidermal differentiation complex protein 6B | late envelope protein 16 | Late cornified envelope protein 3D | SPRL6B | late cornified envelope 3D | small proline rich-like (epidermal differentiation complex) 6A | Small proline-rich-like epidermal differentiation complex protein 6B | Small proline rich-like (epidermal differentiation complex) 6B | Small proline rich-like (epidermal differentiation complex) 6A

Late Envelope Protein 16: Unraveling Its Multifaceted Role in Cell Signaling Pathways

Late envelope protein 16 (LCE16) is a protein that is expressed in many different tissues throughout the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the lateenvelope family of proteins, which are involved in the regulation of cell signaling pathways.

One of the key functions of LCE16 is its role in the regulation of neurotransmitter release from nerve axons. This is important for the proper functioning of the nervous system, as neurotransmitters are responsible for transmitting signals between neurons and other cells. When neurotransmitters are released from axons, they can interact with their receptors, which are located on the surface of neuronal cells. This interaction is critical for the transmission of signals, and LCE16 plays a key role in this process.

Another function of LCE16 is its role in the regulation of cell signaling pathways that are involved in cancer. LCE16 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. This pathway is often disrupted in cancer, and LCE16 has been shown to play a role in restoring this pathway.

In addition to its role in cell signaling pathways, LCE16 has also been shown to be involved in the regulation of inflammation. This is important because inflammation can contribute to a variety of diseases, including cancer, heart disease, and neuroinflammatory disorders. shown to be involved in the regulation of the immune response, and it has been shown to play a role in the regulation of inflammatory cytokine production.

Despite its involvement in a number of important biological processes, LCE16 is not yet a well-studied protein. There are only a few studies that have investigated its functions, and more research is needed to fully understand its role in the regulation of cell signaling pathways and other biological processes.

In conclusion, LCE16 is a protein that is expressed in many different tissues throughout the body and is involved in the regulation of cell signaling pathways, including neurotransmitter release and cancer. It is also involved in the regulation of inflammation and may be a drug target or biomarker. Further research is needed to fully understand its role in these processes and to develop new treatments for a variety of diseases.

Protein Name: Late Cornified Envelope 3D

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE3D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE3D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LCE3E | LCE4A | LCE5A | LCE6A | LCIIAR | LCK | LCLAT1 | LCMT1 | LCMT2 | LCN1 | LCN10 | LCN12 | LCN15 | LCN1P1 | LCN1P2 | LCN2 | LCN6 | LCN8 | LCN9 | LCNL1 | LCOR | LCORL | LCP1 | LCP2 | LCT | LCT-AS1 | LCTL | LDAF1 | LDAH | LDB1 | LDB2 | LDB3 | LDC1P | LDHA | LDHAL6A | LDHAL6B | LDHAL6CP | LDHAP5 | LDHB | LDHBP1 | LDHC | LDHD | LDLR | LDLRAD1 | LDLRAD2 | LDLRAD3 | LDLRAD4 | LDLRAP1 | LDOC1 | LEAP2 | LECT2 | LEF1 | LEF1-AS1 | LEFTY1 | LEFTY2 | LEKR1 | LELP1 | LEMD1 | LEMD1-AS1 | LEMD2 | LEMD3 | LENEP | LENG1 | LENG8 | LENG8-AS1 | LENG9 | LEO1 | LEP | LEPR | LEPROT | LEPROTL1 | LERFS | LETM1 | LETM2 | LETMD1 | LETR1 | Leukotriene B4 receptor (LTB4-R) | Leukotriene CysLT receptor | LEUTX | LEXM | LFNG | LGALS1 | LGALS12 | LGALS13 | LGALS14 | LGALS16 | LGALS17A | LGALS2 | LGALS3 | LGALS3BP | LGALS4 | LGALS7 | LGALS7B | LGALS8 | LGALS8-AS1 | LGALS9 | LGALS9B | LGALS9C | LGALSL | LGI1